Innovata (LSE: IOV) is an interesting little drug development company. It’s recently moved into the black, has cash on the balance sheet, and it might announce a major partnering deal in the next six months or so.
Let’s look at the numbers first. Last year the company made a loss, but in the first half of this year Innovata swung into the black and announced an operating profit of £7.2m on revenue of £18.5m. It also highlighted a £20.1m cash pile….
Continue reading this article at the Motley Fool